All In Biotech

Drug Trial Radar · NCT06995651

Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis

Pharmacokinetic and Pharmacodynamic Effects of Dorzagliatin in Pancreatic Insufficient-Cystic Fibrosis: A Randomized Double-blind, Cross-over Trial

Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Oct 21, 2025

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Michael R. Rickels, MD, MSAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to determine the pharmacokinetic and pharmacodynamic response of dorzagliatin 50 mg twice daily following 7-day administration in individuals with pancreatic insufficient cystic fibrosis and abnormal glucose tolerance when compared to randomized, double-blind 7-day administration of placebo in a cross-over fashion. We hypothesize that dorzagliatin administration will result in significant drug concentrations and improved glucose tolerance, early-phase insulin secretion, glucagon suppression, and hepatic glycogen storage assessed during a standardized mixed-meal tolerance test.

Conditions

  • Pancreatic Insufficiency
  • Cystic Fibrosis-related Diabetes

Interventions

  • DorzagliatinDrug

    Randomized, double-blind, cross-over study of Dorzagliatin 50 mg orally twice daily for 7 days compared to matched-placebo orally twice daily for 7 days.

  • PlaceboDrug

    Randomized, double-blind, cross-over study of Dorzagliatin 50 mg orally twice daily for 7 days compared to matched-placebo orally twice daily for 7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Drug concentrations (PK; Cmax)Time frame: 2 months
  2. Glucose tolerance (PD)Time frame: 2 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital of University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • University of Pennsylvania Center for Human Phenomic Science (CHPS)

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.